Bridge Medicines receives $10 million capital infusion from investors Takeda Pharmaceutical Company Ltd., Bay City Capital, and Deerfield
NEW YORK, NEW YORK – November 12, 2020
Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the additional funding of $10 million to advance its current pipeline of products as well as expand with additional in-licensed technologies.
Bridge Medicines, launched in 2016 by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management Company and Bay City Capital, is a groundbreaking initiative that extends the work of the independent, non-profit Tri-Institutional Therapeutics Discovery Institute.